MV BioTherapeutics has developed modified microorganisms and recombinant proteins with unique potentials in a wide range of therapeutic indications

MV BioTherapeutics ApyraMed

ApyraMed exploits as active principle, apyrase alone or in different dosage/combination (including live biotherapeutics) to enhance endogenous secretory IgA in pathophysiological conditions.

MV BioTherapeutics ApyraVax

ApyraVax exploits apyrase in different vectors and drug combinations to elicit specific mucosal responses conferring protection against infection by pathogens.